GR-MD-02 + Pembrolizumab Versus Pembrolizumab Monotherapy in Melanoma and Squamous Cell Head and Neck Cancer Patients
Status:
Suspended
Trial end date:
2030-08-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to test the safety & efficacy of combination drugs versus
placebo to treat metastatic melanoma and head and neck squamous cell carcinoma.
Phase:
Phase 2
Details
Lead Sponsor:
Providence Health & Services
Collaborator:
Providence Cancer Center, Earle A. Chiles Research Institute